Technologies Inc.

Bringing Epigenetic Technology and
Artificial Intelligence to Life.

What We Do

life insurance
FOXO LABS is creating next-gen underwriting protocols & consumer value propositions for the global life insurance industry.

Ai-powered epigenetic technology
Our goal is to eliminate underwriting friction, and offer health and wellness insights with ai-powered epigenetic technology.

Data privacy built with scalable infrastructure
Our technology is built with best-in-class technology and infrastructure with data privacy being our top priority.

Proprietary technology
Our proprietary epigenetic biomarker technology will introduce next-gen underwriting protocals for life insurance carriers.

World class science team & partnerships
All of our science is built by our world class science team and has been rigorously validated by leading industry experts.

Why We Do It

We believe that epigenetic technology offers new
understanding and insights into aging and disease.

That maturation of genetic sequencing technology platforms, coupled with emerging artificial intelligence (AI) and bioinformatics tools is allowing us to understand human biology in ways never imagined.

We specialize in discovering and understanding the role epigenetics, or gene expression, plays in individual health, wellness, and aging. We provide services and tools to the industries we serve in order to improve human health.

While a person’s underlying genetic code is stable throughout life, the mechanisms that drive their gene expression is a rapidly evolving science. We look at how DNA methylation relates to specific aspects of health, wellness, and aging. Our epigenome is the combination of natural and environmental modifications that imprint biomarkers to leave a unique biography of an individual’s health and wellness history.

How changes to the human epigenome can cause genes to express in a way that causes chronic illness and disease.
Smoking tobacco is a leading cause of cancer
Stress promotes Cardiovascular Disease
Obesity can cause genes to express as Diabetes
Diet & Exercise can increase/decrease Disease States

How We Do It

We identify epigenetic biomarkers along the epigenome by applying advanced automated machine learning and artificial intelligence technologies to create predictive models that correlate epigenetic profiles with states of health, wellness, disease, and aging. 

We ensure our data is prepped, quality-checked, and organized via custom bioinformatics pipelines to ensure reliable analyses.  

We support high throughput human and mouse epigenetic methylation and DNA array testing through CLIA certified laboratories.

Who we serve


We develop epigenetic technologies that are supporting researchers with new tools and analyses.


Longevity Insurance

We are creating a next-generation underwriting protocol that eliminates blood and urine specimen collection while improving accuracy.

Longevity Insurance

FOXO team

We are a team of professionals covering a broad spectrum of expertise that ranges from entrepreneurial growth, molecular biology, and machine learning to computer science, finance, and marketing.

Jon R. Sabes, Founder & CEO of FOXO BioScience

Jon R. Sabes

CEO & Founder

Jon R. Sabes is an entrepreneur with over 25 years of experience in life insurance innovation, finance, venture capital, and business development. As a health-obsessed ultra-athlete, he has spent the last decade finding ways to transform life insurance by using advances in molecular biotechnology to improve human health and longevity. He holds a Doctor of Law (J.D.) from the University of Minnesota and a bachelor’s degree in economics from the University of Colorado.

Brian Chen, PhD, Chief Science Officer at FOXO BioScience

Brian Chen, PhD

Chief Science Officer

Brian Chen is an epidemiologist with over 40 peer-reviewed scientific publications on the biology of aging, genomics, epidemiology, chronic diseases and data science, including Dr. Steve Horvath’s seminal paper on the "epigenetic clock." He did his postdoctoral research at the National Institute on Aging (NIA) and the National Heart, Lung, and Blood Institute's Framingham Heart Study. He holds a PhD in epidemiology from UCLA and an MPH from the University of California at Berkeley.

Erin Sharoni

Chief Product Officer

Erin is an accomplished creative with over 15 years of experience building products and brands in molecular health, media, and finance. Her multidisciplinary approach to problem-solving is driven by a lifelong commitment to the intersection of science and art, and she is passionate about disruptive technology that improves the human experience. She holds a master's degree in Biology from Harvard and a bachelor's degree with honors in Studio Art from Wesleyan University.

Robby Potashnick

Chief Financial Officer

Robby Potashnick is a proven finance leader with over a decade of experience in established global financial services and Healthcare companies, such as United Health Group and PwC. He holds an MBA from Kellstadt Graduate School of Business at DePaul University and a master’s degree in Accountancy from Gies College of Business at the University of Illinois Urbana-Champaign.

Tyler Danielson

Chief Technology Officer

Tyler Danielson is a skilled technology leader with deep experience leveraging software for modern life insurance products. He has served in leadership roles at insurtech and fintech companies, including Cargill and brightpeak financial, and holds a master’s degree in Computer Science from the University of Minnesota.

Michael Will, Senior Counsel at FOXO BioScience

Michael Will

General Counsel

Michael Will has a proven history of managing legal and compliance needs for the life insurance industry. Before joining FOXO, he served as Senior Counsel at an insurtech startup, brightpeak financial—a division of Thrivent Financial. He holds a J.D. from the University of St. Thomas School of Law.

Follow FOXO

Stay up to date on the latest updates in science and technology by following FOXO Technologies on Twitter or reading our CEO Jon Sabes’ personal blog.


Our partners

We collaborate with some of the nation’s leading bioscience and biotechnology companies, academic institutions, and science education organizations to develop cutting-edge epigenetic technology.

Featured articles



FOXO Technologies Inc. (“FOXO”) today announced that it has closed a $10 million investment led by healthcare and technology investor Bespoke Growth Partners, Inc.


FOXO in Coverager & SCOR

Learn how we are modernizing the longevity insurance industry with a new underwriting protocol and a reimagined customer engagement platform to improve healthspan and lifespan.


FOXO in On the Risk

Read about the current state of insurance underwriting and how we are using molecular biotechnology to reimagine it in “The Need to Evolve Preferred Underwriting” by FOXO Chief Underwriter, Bill Moore.


Epigenetics & Longevity


Epigenetic Aging: How old is your DNA?

Dr. Steve Horvath, a professor of genetics and biostatistics at UCLA, has found a way to measure biological aging – a type of “clock” – based on the methylation pattern of an organism’s genome.

David Sinclair & Joe Rogan

Our journey started with Dr. Steve Horvath’s research into aging. Listen to Dr. David Sinclair explain who Dr. Horvath is and why our technology is fundamental to understanding aging.

The Power of the
Epigenetic Clock

In this TEDxBerkeley Talk, Dr. Steve Horvath of the University of California, Los Angeles explores how epigenetic clocks are currently being used to discover anti-aging treatments.